ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Discovery of Surface-Engineered Nanoparticles That Boost Enzyme Activity via High-Throughput Screening and Machine Learning.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Artificial intelligence-guided nanozyme engineering for chronic wound healing: from rational design to precision therapeutics.Bioactive materials · 2027Review
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Short Peptoid Capping Ligands Stabilize Dispersion of Gold Nanospheres in Aqueous Solutions.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- Discovery of Surface-Engineered Nanoparticles That Boost Enzyme Activity via High-Throughput Screening and Machine Learning.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nanoparticles (NPs) are known to enhance the activity of enzymes, but such findings remain largely empirical, lacking predictive design principles. Here, the first high-throughput platform for the discovery of surface-engineered nanoparticles (SENs) that modulate enzyme function is introduced. Guided by the hypothesis that surface ligands are primary drivers of activity enhancement, a library of 194 gold- and palladium-based SENs functionalized with diverse peptide ligands is synthesized. These SENs are screened against three model enzymes: cytochrome c, lactoperoxidase (LPO), and lipase. Multiple SENs substantially increased enzymatic activity, with the most effective achieving ≈19-fold increase. The resulting dataset enabled the training of a machine learning model that identified key ligand features associated with high-performing SENs, establishing a predictive framework for designing activity-enhancing NPs. Mechanistic studies confirm that the ligand shell plays a dominant role in driving enhancement, suggesting that effective ligands identified via this approach can be readily transferred across NP platforms. To demonstrate functional relevance, it is shown that an optimized SEN/LPO pair outperforms LPO in inhibiting the growth of multidrug-resistant bacteria and disrupting biofilm formation. Collectively, this work offers a scalable and generalizable method to map and harness nanoscale structure-function relationships at biointerfaces, with applications in biocatalysis, biosensing, and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.